Clarity receives FDA Fast Track Designation for 64Cu-SAR-bisPSMA
- Written by PR Newswire Asia - Asian Spectator
![]() |
SYDNEY, Aug. 22, 2024 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, is pleased to announce that the U.S. Food and Drug Administration (FDA) has granted Fast Track...